Molecular Mechanisms of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in Mesothelioma
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26094299 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Taketo Kato und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Japan. Hauptthemen laut MEDLINE: Mesothelioma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Aichi Cancer Research Foundation.
Abstract (Originalsprache)
Mesothelioma is characterized by the inactivation of tumor suppressor genes, with frequent mutations in neurofibromin 2 (NF2), BRCA1-associated protein 1 (BAP1), and cyclin-dependent kinase inhibitor 2A (CDKN2A). These mutations lead to disruptions in the Hippo signaling pathway and histone methylation, thereby promoting tumor growth. NF2 mutations result in Merlin deficiency, leading to uncontrolled cell proliferation, whereas BAP1 mutations impair chromatin remodeling and hinder DNA damage repair. Emerging molecular targets in mesothelioma include mesothelin (MSLN), oxytocin receptor (OXTR), protein arginine methyltransferase (PRMT5), and carbohydrate sulfotransferase 4 (CHST4). MSLN-based therapies, such as antibody–drug conjugates and immunotoxins, have shown efficacy in clinical trials. OXTR, upregulated in mesothelioma, is correlated with poor prognosis and represents a novel therapeutic target. PRMT5 inhibition is being explored in tumors with MTAP deletions, commonly co-occurring with CDKN2A loss. CHST4 expression is associated with improved prognosis, potentially influencing tumor immunity. Immune checkpoint inhibitors targeting PD-1/PD-L1 have shown promise in some cases; however, resistance mechanisms remain a challenge. Advances in multi-omics approaches have improved our understanding of mesothelioma pathogenesis. Future research will aim to identify novel therapeutic targets and personalized treatment strategies, particularly in the context of epigenetic therapy and combination immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Japan.
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Japan.
ORCID-Profile: Taketo Kato, Harushi Ueno, Shota Nakamura, Toyofumi Fengshi Chen-Yoshikawa
Förderung
- Aichi Cancer Research Foundation
Zitieren
APA
Kato, T., Tanaka, I., Huang, H., Okado, S., Imamura, Y., Nomata, Y., Takenaka, H., Watanabe, H., Kawasumi, Y., Nakanishi, K., Kadomatsu, Y., Ueno, H., Nakamura, S., Mizuno, T., & Chen-Yoshikawa, T. F. (2025). Molecular Mechanisms of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in Mesothelioma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26094299
Vancouver
Kato T, Tanaka I, Huang H, Okado S, Imamura Y, Nomata Y, et al. Molecular Mechanisms of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in Mesothelioma. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26094299
BibTeX
@article{Kato2025,
author = {Kato, Taketo and Tanaka, Ichidai and Huang, Heng and Okado, Shoji and Imamura, Yoshito and Nomata, Yuji and Takenaka, Hirofumi and Watanabe, Hiroki and Kawasumi, Yuta and Nakanishi, Keita and Kadomatsu, Yuka and Ueno, Harushi and Nakamura, Shota and Mizuno, Tetsuya and Chen-Yoshikawa, Toyofumi Fengshi},
title = {Molecular Mechanisms of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in Mesothelioma},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26094299}
}
EUVIMED